Armistice Capital LLC Boosts Position in BridgeBio Oncology Therapeutics, Inc $BBOT

Armistice Capital LLC raised its position in BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) by 142.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,000,000 shares of the company’s stock after acquiring an additional 588,000 shares during the quarter. Armistice Capital LLC owned approximately 1.25% of BridgeBio Oncology Therapeutics worth $12,520,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in BBOT. CIBC Private Wealth Group LLC purchased a new position in shares of BridgeBio Oncology Therapeutics in the fourth quarter worth approximately $63,000. Persistent Asset Partners Ltd purchased a new stake in BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $107,000. Squarepoint Ops LLC bought a new position in BridgeBio Oncology Therapeutics in the fourth quarter worth approximately $144,000. BIT Capital GmbH purchased a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $313,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $670,000. 54.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BBOT has been the subject of several analyst reports. HC Wainwright upped their price objective on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Wall Street Zen downgraded BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Canaccord Genuity Group assumed coverage on BridgeBio Oncology Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $23.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $25.00.

BridgeBio Oncology Therapeutics Stock Performance

NASDAQ BBOT opened at $7.68 on Thursday. The company has a market capitalization of $615.24 million, a price-to-earnings ratio of -3.75 and a beta of 0.29. The stock has a 50-day simple moving average of $8.43. BridgeBio Oncology Therapeutics, Inc has a twelve month low of $7.00 and a twelve month high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last issued its earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that BridgeBio Oncology Therapeutics, Inc will post -2.32 earnings per share for the current fiscal year.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.